Mucosal IL-12 is more effective than systemic IL-12 in augmenting IFN-γ expression and inhibiting allergic lung eosinophilia in murine lungs

Sanjiv Sur, Barun Choudhury, J. S. Lam, P. Bouchard, J. S. Wild, N. Sur, R. Alam, A. Sigounas, D. Holbert, M. R. Van Scott

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The relative efficacy of mucosal (intratracheal) and systemic (intraperitoneal) delivery of interleukin (IL)-12 was evaluated in a mouse model of allergic lung eosinophilia. Mucosal administration of IL-12 achieved 100- to 600-fold higher bronchoalveolar lavage (BAL) levels of IL-12, but 2- to 10-fold lower serum levels compared to systemic administration. Whereas both mucosal and systemic IL-12 inhibited BAL eosinophil recruitment at high doses (100-1000 ng), only mucosal IL-12 was effective at low doses (1-10 ng). Mucosal, but not systemic, administration of 1000 ng of IL-12 increased interferon (IFN)-γ expression in BAL cells. In a model of ongoing eosinophilic inflammation, when mucosal or systemic IL-12 doses were initiated prior to peak eosinophilia, further eosinophil recruitment was inhibited. However, when IL-12 treatment was initiated after peak eosinophil recruitment occurred, recovery from eosinophilic inflammation was not facilitated. Our findings are the first to demonstrate that locally administered IL-12 inhibits eosinophil recruitment at 100-fold lower doses than systemic IL-12. The most likely mechanism of this enhanced inhibitory activity is a sustained increase in lung levels of IL-12 that augments IFN-γ production from BAL cells. We suggest that future studies should evaluate the efficacy of low doses of nebulized IL-12 in inhibiting eosinophilic lung inflammation in asthma.

Original languageEnglish (US)
Pages (from-to)457-476
Number of pages20
JournalExperimental Lung Research
Volume26
Issue number6
StatePublished - 2000

Fingerprint

Eosinophilia
Interleukin-12
Interferons
Lung
Bronchoalveolar Lavage
Eosinophils
Mucosal Administration
Inflammation
Interleukin-2
Pneumonia
Asthma

Keywords

  • Asthma
  • Eosinophils
  • IFN-γ
  • IL-12
  • Th1
  • Th2

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Sur, S., Choudhury, B., Lam, J. S., Bouchard, P., Wild, J. S., Sur, N., ... Van Scott, M. R. (2000). Mucosal IL-12 is more effective than systemic IL-12 in augmenting IFN-γ expression and inhibiting allergic lung eosinophilia in murine lungs. Experimental Lung Research, 26(6), 457-476.

Mucosal IL-12 is more effective than systemic IL-12 in augmenting IFN-γ expression and inhibiting allergic lung eosinophilia in murine lungs. / Sur, Sanjiv; Choudhury, Barun; Lam, J. S.; Bouchard, P.; Wild, J. S.; Sur, N.; Alam, R.; Sigounas, A.; Holbert, D.; Van Scott, M. R.

In: Experimental Lung Research, Vol. 26, No. 6, 2000, p. 457-476.

Research output: Contribution to journalArticle

Sur, S, Choudhury, B, Lam, JS, Bouchard, P, Wild, JS, Sur, N, Alam, R, Sigounas, A, Holbert, D & Van Scott, MR 2000, 'Mucosal IL-12 is more effective than systemic IL-12 in augmenting IFN-γ expression and inhibiting allergic lung eosinophilia in murine lungs', Experimental Lung Research, vol. 26, no. 6, pp. 457-476.
Sur, Sanjiv ; Choudhury, Barun ; Lam, J. S. ; Bouchard, P. ; Wild, J. S. ; Sur, N. ; Alam, R. ; Sigounas, A. ; Holbert, D. ; Van Scott, M. R. / Mucosal IL-12 is more effective than systemic IL-12 in augmenting IFN-γ expression and inhibiting allergic lung eosinophilia in murine lungs. In: Experimental Lung Research. 2000 ; Vol. 26, No. 6. pp. 457-476.
@article{f7bbee0dd3344249aa8a9792f6973bd7,
title = "Mucosal IL-12 is more effective than systemic IL-12 in augmenting IFN-γ expression and inhibiting allergic lung eosinophilia in murine lungs",
abstract = "The relative efficacy of mucosal (intratracheal) and systemic (intraperitoneal) delivery of interleukin (IL)-12 was evaluated in a mouse model of allergic lung eosinophilia. Mucosal administration of IL-12 achieved 100- to 600-fold higher bronchoalveolar lavage (BAL) levels of IL-12, but 2- to 10-fold lower serum levels compared to systemic administration. Whereas both mucosal and systemic IL-12 inhibited BAL eosinophil recruitment at high doses (100-1000 ng), only mucosal IL-12 was effective at low doses (1-10 ng). Mucosal, but not systemic, administration of 1000 ng of IL-12 increased interferon (IFN)-γ expression in BAL cells. In a model of ongoing eosinophilic inflammation, when mucosal or systemic IL-12 doses were initiated prior to peak eosinophilia, further eosinophil recruitment was inhibited. However, when IL-12 treatment was initiated after peak eosinophil recruitment occurred, recovery from eosinophilic inflammation was not facilitated. Our findings are the first to demonstrate that locally administered IL-12 inhibits eosinophil recruitment at 100-fold lower doses than systemic IL-12. The most likely mechanism of this enhanced inhibitory activity is a sustained increase in lung levels of IL-12 that augments IFN-γ production from BAL cells. We suggest that future studies should evaluate the efficacy of low doses of nebulized IL-12 in inhibiting eosinophilic lung inflammation in asthma.",
keywords = "Asthma, Eosinophils, IFN-γ, IL-12, Th1, Th2",
author = "Sanjiv Sur and Barun Choudhury and Lam, {J. S.} and P. Bouchard and Wild, {J. S.} and N. Sur and R. Alam and A. Sigounas and D. Holbert and {Van Scott}, {M. R.}",
year = "2000",
language = "English (US)",
volume = "26",
pages = "457--476",
journal = "Experimental Lung Research",
issn = "0190-2148",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Mucosal IL-12 is more effective than systemic IL-12 in augmenting IFN-γ expression and inhibiting allergic lung eosinophilia in murine lungs

AU - Sur, Sanjiv

AU - Choudhury, Barun

AU - Lam, J. S.

AU - Bouchard, P.

AU - Wild, J. S.

AU - Sur, N.

AU - Alam, R.

AU - Sigounas, A.

AU - Holbert, D.

AU - Van Scott, M. R.

PY - 2000

Y1 - 2000

N2 - The relative efficacy of mucosal (intratracheal) and systemic (intraperitoneal) delivery of interleukin (IL)-12 was evaluated in a mouse model of allergic lung eosinophilia. Mucosal administration of IL-12 achieved 100- to 600-fold higher bronchoalveolar lavage (BAL) levels of IL-12, but 2- to 10-fold lower serum levels compared to systemic administration. Whereas both mucosal and systemic IL-12 inhibited BAL eosinophil recruitment at high doses (100-1000 ng), only mucosal IL-12 was effective at low doses (1-10 ng). Mucosal, but not systemic, administration of 1000 ng of IL-12 increased interferon (IFN)-γ expression in BAL cells. In a model of ongoing eosinophilic inflammation, when mucosal or systemic IL-12 doses were initiated prior to peak eosinophilia, further eosinophil recruitment was inhibited. However, when IL-12 treatment was initiated after peak eosinophil recruitment occurred, recovery from eosinophilic inflammation was not facilitated. Our findings are the first to demonstrate that locally administered IL-12 inhibits eosinophil recruitment at 100-fold lower doses than systemic IL-12. The most likely mechanism of this enhanced inhibitory activity is a sustained increase in lung levels of IL-12 that augments IFN-γ production from BAL cells. We suggest that future studies should evaluate the efficacy of low doses of nebulized IL-12 in inhibiting eosinophilic lung inflammation in asthma.

AB - The relative efficacy of mucosal (intratracheal) and systemic (intraperitoneal) delivery of interleukin (IL)-12 was evaluated in a mouse model of allergic lung eosinophilia. Mucosal administration of IL-12 achieved 100- to 600-fold higher bronchoalveolar lavage (BAL) levels of IL-12, but 2- to 10-fold lower serum levels compared to systemic administration. Whereas both mucosal and systemic IL-12 inhibited BAL eosinophil recruitment at high doses (100-1000 ng), only mucosal IL-12 was effective at low doses (1-10 ng). Mucosal, but not systemic, administration of 1000 ng of IL-12 increased interferon (IFN)-γ expression in BAL cells. In a model of ongoing eosinophilic inflammation, when mucosal or systemic IL-12 doses were initiated prior to peak eosinophilia, further eosinophil recruitment was inhibited. However, when IL-12 treatment was initiated after peak eosinophil recruitment occurred, recovery from eosinophilic inflammation was not facilitated. Our findings are the first to demonstrate that locally administered IL-12 inhibits eosinophil recruitment at 100-fold lower doses than systemic IL-12. The most likely mechanism of this enhanced inhibitory activity is a sustained increase in lung levels of IL-12 that augments IFN-γ production from BAL cells. We suggest that future studies should evaluate the efficacy of low doses of nebulized IL-12 in inhibiting eosinophilic lung inflammation in asthma.

KW - Asthma

KW - Eosinophils

KW - IFN-γ

KW - IL-12

KW - Th1

KW - Th2

UR - http://www.scopus.com/inward/record.url?scp=0033797311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033797311&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 457

EP - 476

JO - Experimental Lung Research

JF - Experimental Lung Research

SN - 0190-2148

IS - 6

ER -